83846-78-0

Basic information

• Product Name: (3,4-diaminophenyl) (2-thienyl) ketone
• Synonyms: (3,4-diaminophenyl) (2-thienyl) ketone;(3,4-Diaminophenyl)thiophen-2-ylmethanone;Einecs 281-057-0
• CAS NO: 83846-78-0
• Molecular Formula: C₁₁H₁₀N₂OS
• Molecular Weight: 218.2749
• EINECS: 281-057-0
• Mol File: 83846-78-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 461.7°C at 760 mmHg
• Flash Point: 233°C
• Appearance: /
• Density: 1.35g/cm³
• Vapor Pressure: 1.05E-08mmHg at 25°C
• Refractive Index: 1.706
• CAS DataBase Reference: (3,4-diaminophenyl) (2-thienyl) ketone(CAS DataBase Reference)
• NIST Chemistry Reference: (3,4-diaminophenyl) (2-thienyl) ketone(83846-78-0)
• EPA Substance Registry System: (3,4-diaminophenyl) (2-thienyl) ketone(83846-78-0)

Safety Data

• Hazardous Substances Data: 83846-78-0(Hazardous Substances Data)

Usage

Description

(3,4-diaminophenyl) (2-thienyl) ketone is a chemical compound with the molecular formula C12H11NOS, belonging to the ketone and aromatic amine groups. It is a yellow crystalline solid with a molecular weight of 217.29 g/mol.

Uses

Used in Pharmaceutical Industry:
(3,4-diaminophenyl) (2-thienyl) ketone is used as a building block for the synthesis of various pharmaceuticals and organic compounds. It is particularly valuable in the development of cancer drugs due to its potential biological activities.
Used in Dye and Pigment Production:
(3,4-diaminophenyl) (2-thienyl) ketone is used as a precursor in the production of dyes and pigments, contributing to the creation of a wide range of colorants for various applications.
Used in Heterocyclic Compound Synthesis:
(3,4-diaminophenyl) (2-thienyl) ketone is used as a key intermediate in the synthesis of heterocyclic compounds, which are important in various chemical and pharmaceutical processes.
It is important to handle (3,4-diaminophenyl) (2-thienyl) ketone with caution due to potential health risks, and it should be used in accordance with safety guidelines.

InChI:InChI=1/C11H10N2OS/c12-8-4-3-7(6-9(8)13)11(14)10-2-1-5-15-10/h1-6H,12-13H2

Upstream product

• 528-45-0 3,4-dinitrobenzoic acid 
• 24376-18-9 3,4-dinitrobenzoyl chloride 
• 1438897-51-8 (3,4-dinitrophenyl)(thiophen-2-yl)methanone 

Downstream Products

• 66939-50-2 [5-(thiophene-2-carbonyl)-1⁽³⁾H-benzoimidazol-2-yl]-carbamic acid 2-phenoxy-ethyl ester 
• 66939-46-6 [5-(thiophene-2-carbonyl)-1⁽³⁾H-benzoimidazol-2-yl]-carbamic acid benzyl ester 
• 66939-51-3 [5-(thiophene-2-carbonyl)-1⁽³⁾H-benzoimidazol-2-yl]-carbamic acid 2-phenoxy-propyl ester 

Relevant articles and documents

Indole derivatives, Abl kinase inhibiting composition and pharmaceutical compositions for prevention and treatment of abnormal cell growth diseases comprising the same

PURPOSE: An indole derivative compound, and an Abl kinase inhibitor composition and a pharmaceutical composition for preventing and treating abnormal cell growth diseases containing the same are provided to treat diseases caused by abnormal cell growth, function, or behavior, especially cancer, immune diseases, cardiovascular diseases, viral infectious diseases, inflammatory diseases, endocrine diseases, and neurological diseases. CONSTITUTION: An indole derivative of chemical formula 1 or a pharmaceutically acceptable salt is provided. A pharmaceutical composition for suppressing wild type Abl kinase and mutant type Abl (T315I) kinase contains the compound as an active ingredient and a pharmaceutically acceptable carrier or diluents. A pharmaceutical composition for treating proliferative diseases, immune diseases, cardiovascular diseases, neurological diseases, inflammatory diseases, endocrine diseases, or viral infectious diseases contains the compound as an active ingredient and a pharmaceutically acceptable carrier or diluents.

Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-abelson kinase including the T315i mutant

The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (Bcr-Abl) kinase domain remains a clinical challenge due to limited effective treatment options for chronic myeloid leukemia (CML). Herein we report a novel series of benzothiazole-based inhibitors that are effective against wild-type and T315I mutant Bcr-Abl kinases. The original hit compound, nocodazole, was extensively modified through a structure-based drug design strategy, especially by varying the groups at the C2 and C6 positions of the scaffold. In addition, the introduction of water-solubilizing groups at the terminal ethyl group resulted in enhanced physicochemical properties and potency in cellular inhibition. Several compounds inhibited the kinase activity of both wild-type Bcr-Abl and the T315I mutant with IC50 values in the picomolar range and exhibited good antiproliferative effects on Ba/F3 cell lines transformed with either wild-type or T315I mutant Bcr-Abl.